Study on drug-resistant tuberculosis and tuberculosis treatment on patients with drug resistant tuberculosis in chest clinic outpatient department

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 2, 2012, Pages 733-737

  Kurniawati, Fivy ^a,b   Sulaiman, Syed Azhar Syed ^b   Gillani, Syed Wasif ^b  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Drug resistant tuberculosis; Monodrug resistant; Multidrug resistant; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; ASIAN; CHINESE; CIGARETTE SMOKING; CROSS-SECTIONAL STUDY; DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; RACE DIFFERENCE; SUBSTANCE ABUSE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 84859994277     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Phatophysiologic Approach. 6th ed. United States of America: The McGraw-Hill Companies; 2005.
2. Breathnach AS, Rutier AD, Holdsworth GMC, et al. An Outbreak of Multidrug-Resistant Tuberculosis in a London Teaching Hospital. Journal of Hospital Infection 1998;39:111-117.
3. Ahmad S, Mokaddas E. Recent Advances in the Diagnosis and Treatment of Multidrug-resistant Tuberculosis. Respiratory Medicine 2009;103:1777-1790.
4. WHO. Global Tuberculosis Control: WHO Report 2010. In. Gneva: World Health Organization; 2010.
5. Bartu V, Kopecka E. Multidrug-resistant Tuberculosis-Prolonged Course of Disease. Respiratory Medicine 2008;1:150-152.
6. Tang YW, Stratton CW, Kilic A, Drake W. Advances in the Diagnosis of Mycobacterium tuberculosis and Detection of Drug Resistance. In: Advanced Techniques in Diagnostic Microbiology: Springer US; 2006.
7. Shah NS, Pratt R, Amstrong L, Robinson V, Castro KG, Cegielski JP. Extensively Drug-Resistant Tunberculosis in The United States, 1993-2007. JAMA 2008;300(18):2153-2160.
8. Sharma SK, Turaga KK, Balamurugan A, et al. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infection, Genetics and Evolution 2003;3:183-188.
9. Rindi L, Bianchi L, Tortoli E, Lari N, Bonanni D, Garzelli C. A real-time PCR assay for detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates. Journal of Microbiological Methods 2003; 55:797-800.
10. Tost JR, Vidal R, Maldonado J, Cayla JA. Effectiveness and Tolerance of Antituberculosis Treatment Regiments Without Isoniazid and Rifampicin Analysis of 85 Cases. Arch Bronconeumol 2008;44(9):478-483.
11. Yee D, Valiqquete C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Respir Crit Care Med 2003;167:1472-1477.
12. A. MO, M. FAR, S. A, M. KI. Prevalence and Risk Factor of Anti- Tuberculosis Drug-Induced Hepatitis in Malaysia. Singapore Medical Journal 2008;49 (9):688-693.
13. Marra F, Marra CA, Bruchet N, et al. Adverse Drug Reactions Accociated with First-line Anti-Tuberculosis Drug Regimens. Int J Tuber Lung Dis 2007;11(8):868-875.
14. Sharma DK, Kulshreshtha M, maheshwari M, Yadav S. A Clinical Survey On Correlation Study Between Tuberculosis And Its Predisposing Factors In Mathura Region, International Journal of Pharmaceutical Sciences Review and Research 2011;Volume 9(Issue 2):150-152.
15. Singla R, Sharma SK, Mohan A, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010;132:81-86.
16. Gajalakshmi V, Peto R. Smoking, drinking and incident tuberculosis in rural India: population-based case-control study. International Journal of Epidemiology 2009;38(4):1018-1025.
17. Elamin EI, Ibrahim MIM, Sulaiman SAS, Muttalif AR. Cost of illness of tuberculosis in Penang, Malaysia. Pharm World Sci 2008;30:281-286.
18. Melzer M, Gupta N, Petersen I, Cook S, Hall B. Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK. International Journal of Infectious Diseases 2010;14:e717-e722.
19. Kim HR, Hwang SS, Kim EC, et al. Risk Factor for Multidrug- Resistant Bacterial Infection among Patients with Tuberculosis. Journal of Hospital Infection 2010;3:1-4.
20. Suarez-Garcia I, Rodriguez-Blanco A, Vidal-Perez JL, et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 2009;28:325-330.
21. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. The Lancet 2004;363:474-481.
22. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infectious Disease 2009;9:153-161.